Johnson & Johnson (JNJ) Stock: JASMINE Data Strengthens Lupus Drug Case

TLDR

• JNJ edges higher as JASMINE data backs nipocalimab’s lupus case.

• Nipocalimab shows sustained lupus control in JNJ’s Phase 2 study.

  

• JNJ lupus drug data improves after strong autoantibody-positive results.

• Johnson & Johnson gains support for nipocalimab after JASMINE data.

• JNJ stock steadies as Phase 2 lupus results strengthen drug outlook

Johnson & Johnson (JNJ) reported fresh JASMINE Phase 2 data for nipocalimab, strengthening its lupus drug case. JNJ closed at $222.89, down 0.28%, before rising pre-market to $223.03. The move showed mild recovery as the company highlighted sustained disease control through 52 weeks.

Johnson & Johnson, JNJ

Nipocalimab Meets Key Lupus Trial Goal

Nipocalimab met the primary endpoint at Week 24 in adults with moderate-to-severe systemic lupus erythematosus. The drug reduced disease activity as measured by SRI-4 when added to background medication. As a result, Johnson & Johnson gained stronger clinical support for its FcRn-blocker program.

At Week 24, 53.5% of nipocalimab patients achieved SRI-4 response. Placebo patients on background medication recorded a 46.7% response rate. The trial demonstrated a treatment effect in a difficult-to-treat autoimmune disease group.

The Week 52 data also supported longer disease control. Nipocalimab produced a 53.6% SRI-4 response, while placebo reached 39.7%. More treated patients reached low disease activity versus placebo.

JASMINE Data Supports Autoantibody-Positive Focus

Johnson & Johnson reported stronger results in autoantibody-positive patients. That group represents about 80% of people living with systemic lupus erythematosus. Hence, the data may support a broad commercial case if later trials confirm benefit.

In that predefined group, nipocalimab reached a 58.2% SRI-4 response at Week 52. Placebo recorded 36.1% under the same measure. Moreover, 38.9% of treated patients achieved LLDAS, compared with 18.0% on placebo.

Nipocalimab works by blocking the neonatal Fc receptor. This process lowers harmful IgG autoantibodies linked to lupus inflammation.  Johnson & Johnson says the design aims to preserve important immune functions.

JNJ Advances Lupus Program Toward Phase 3

The JASMINE study gives Johnson & Johnson early proof of FcRn blockade in lupus. It also adds biomarker and drug response evidence for further development. Consequently, the company continues to build its rheumatology pipeline around targeted immune treatments.

The safety profile matched earlier nipocalimab studies. Johnson & Johnson reported no new safety signals from the Phase 2 trial. Common adverse reactions included nasopharyngitis, headache, urinary tract infection, and nausea.

Nipocalimab has FDA Fast Track Designation for systemic lupus erythematosus. The ongoing Phase 3 GARDENIA study is now recruiting patients. JNJ’s lupus outlook now depends on whether late-stage data confirms JASMINE’s signal.

The post Johnson & Johnson (JNJ) Stock: JASMINE Data Strengthens Lupus Drug Case appeared first on CoinCentral.